Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE DM versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE DM versus XYZAL.
PROMETHAZINE DM vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
5 mg orally once daily in the evening.
None Documented
None Documented
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine